Suchergebnisse - (Person:"Liu, Geoffrey")

PubPharm (16)

1

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations : Efficacy and Toxicity as Sequential Therapies

enthalten in: JTO clinical and research reports | 2023

von Lau, S. | Perdrizet, K. | Fung, A. | +14

2

Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival : A Pooled Analysis From the International Lung Cancer Consortium

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von García-Pardo, M. | Chang, A. | Schmid, S. | +20

CommentIn: J Thorac Oncol. 2023 Mar;18(3):254-256. - PMID 36842806

3

Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2023

von Schmid, S. | Cheng, S. | Chotai, S. | +16

4

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Mazieres, J. | Iadeluca, L. | Shaw, A. | +11

5

Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system

enthalten in: Cancer treatment and research communications | 2022

von Perdrizet, K. | Stockley, T. | Law, J. | +20

6

Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer : Single-Institution Analysis, Systematic Review, and Meta-analysis

enthalten in: Clinical lung cancer | 2021

von Chan, S. | Smith, E. | Aggarwal, R. | +14

7

The effect of prior cancer on non-small cell lung cancer trial eligibility

enthalten in: Cancer medicine | 2021

von Herman, M. | Liu, Z. | Shepherd, F. | +3

8

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer

enthalten in: Therapeutic advances in medical oncology | 2021

von Melosky, B. | Cheema, P. | Juergens, R. | +8

9

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer : Results of an Open-Label, Multicenter, Phase 1B Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Felip, E. | de Braud, F. | Maur, M. | +15

CommentIn: J Thorac Oncol. 2020 Mar;15(3):305-307. - PMID 32093849

10

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

enthalten in: Oncotarget | 2017

von Kim, L. | Saieg, M. | Di Maio, M. | +17